Are Dysregulated Inflammatory Responses to Commensal Bacteria Involved in the Pathogenesis of Hepatobiliary-Pancreatic Autoimmune Disease? An Analysis Using Mice Models of Primary Biliary Cirrhosis and Autoimmune Pancreatitis by Yanagisawa, Naoko et al.
International Scholarly Research Network
ISRN Gastroenterology
Volume 2011, Article ID 513514, 8 pages
doi:10.5402/2011/513514
Review Article
AreDysregulated InﬂammatoryResponses toCommensal
BacteriaInvolvedinthePathogenesisofHepatobiliary-Pancreatic
AutoimmuneDisease? An AnalysisUsing Mice Models ofPrimary
BiliaryCirrhosisand AutoimmunePancreatitis
Naoko Yanagisawa,1 IkukoHaruta,1 Ken Kikuchi,2 NoriyukiShibata,3 andJunjiYagi1
1Departments of Microbiology and Immunology, Tokyo Women’s Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, Japan
2Department of Infection Control Science, Faculty of Medicine, Juntendo University, Tokyo, Japan
3Department of Pathology, Tokyo Women’s Medical University, Tokyo, Japan
Correspondence should be addressed to Ikuko Haruta, haruta@research.twmu.ac.jp
Received 28 April 2011; Accepted 17 May 2011
Academic Editors: A. Armuzzi and C.-T. Shun
Copyright © 2011 Naoko Yanagisawa et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
The etiopathogenesis ofmany autoimmunedisorders has not been identiﬁed. The aim of this paper is to focus on the involvement
ofbacterial exposure inthepathogenesisofprimary biliarycirrhosis (PBC) andautoimmunepancreatitis (AIP),bothofwhich are
broadly categorized as autoimmune disorders involving hepatobiliary-pancreatic lesions. Avirulent and/or commensal bacteria,
which may have important role(s) as initiating factors in the pathogenesis of autoimmune disorders such as PBC and AIP, will be
emphasized.
1.AutoimmuneDiseasesAssociated with
Microbial Infection
Autoimmune diseases arise from an overactive immune
response of the body against tissues normally present in
the body. Autoimmune disorders are often described as a
condition involving genetic components. A high prevalence
of autoimmune diseases is observed within families [1].
However, the fact that the prevalence of autoimmune dis-
easesneverreaches100%amongmonozygotictwinssuggests
that both genetic and environmental factors are involved in
the etiology of autoimmune diseases.
Several studies have implicated microbes in the envi-
ronmental etiology of autoimmune disorders based on
observations such as the regression of autoimmune throm-
bocytopenia after the eradication of Helicobacter pylori [2].
In Guillain-Barr´ es y n d r o m e( G B S ) ,a m i n oa c i ds i m i l a r i t i e s
exist between the gangliosides of the nerve system and
the lipopolysaccharides (LPSs) of Campylobacter jejuni,
suggesting that sensitization by microbes may be based on
autoimmunity from molecular mimicry between bacteria
and the targeted system of the host [3, 4]. A common
recent theory of the cause of autoimmune diseases is that an
infectious agent triggers a cycle of events, which leads to the
upregulation of the host immune response to self-antigens
[5, 6].
2.Innate Immunity Sensitized by Bacteriaasan
Environmental Factorin theEtiologyof PBC
Primary biliarycirrhosis (PBC)isachronicautoimmunedis-
order characterized by chronic nonsuppurative destructive
cholangitis (CNSDC) of small intrahepatic bile ducts and
epithelioid granuloma formation in the portal area, which
leads to progressive ductopenia [7, 8]. The pathogenesis
of biliary epithelial cell damage in PBC is not clearly
understood. However, the relationship between bacterial
infection and the pathogenesis of PBC through the mecha-
nism of molecular mimicry has become a focus of attention.
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in the epithelioid granulomas of PBC patients [9]. Sera from
patients with PBC have been reported to react with both
human and Escherichia colipyruvate dehydrogenase complex
E2 (PDC-E2) [10], and such reactivity of antimitochondrial
antibodies (AMAs) to both human and bacterial molecules
has stimulated speculations that PBC may be induced by
exposure to enterobacterial antigens, perhaps by sharing
molecular mimicry with mitochondrial antigens in PBC.
Other reports indicating bacterial involvement in the etiol-
ogy of PBC include the reported presence of AMAs, which
reacted to Novosphingobium aromaticivorans in sera from
PBC patients [11], and cross-reactivity detected between
Lactobacillusdelbrueckii beta-galactosidase andPDC-E2with
AMA [12]. A link between toll-like receptors (TLRs) and
PBC has also been reported. The elevated expression of
TLR4 has been observed in intrahepatic bile duct epithelial
cells in PBC [13]. Bacterial components, such as LPSs and
the TLR9 ligand CpG DNA, trigger peripheral lymphocytes,
monocytes, and bile epithelial cells to produce cytokines
and AMAs, suggesting that the pathogenesis of PBC is
mediated through TLRs [13–17]. Moreover, elevated levels
of immunoglobulin M (IgM) in PBC have been reported to
result from the CpG DNA stimulation of TLR signalling,
leading to the appearance of IgM-positive memory B cells
[18].
We previously reported that theG r a m - p o s i t i v eb a c t e r i a l
cell wall component lipoteichoic acid (LTA) was detected at
theportaltractintheliversofPBCpatientswithCNSDCand
that PBC patients had higher serum IgA class anti-LTA titers,
when compared with healthy donors [19]. We analyzed the
immunoreactivity against 15 strains from diﬀerent species
of the streptococcal genus using various sera from PBC
patientsandperformedfurtherassaysusingﬁvestrainsofthe
Streptococcusanginosus group,thetitersofwhich were higher
than those of the other strains, and found that the PBC
patient’s sera had the highest IgM class titers to Streptococcus
intermedius [20]. Generally, PBC is characterized by a high
serum level of IgM [21]. Our observation may indicate
that IgM, in part, is involved in the streptococcal-mediated
inﬂammatory response in PBC.
S. intermedius forms part of the commensal bacteria
in the oral cavity, attaching to a surface, forming matrix-
enclosed bioﬁlms in dental plaques, and thereby exhibiting
increased resistance to antimicrobials and to host immune
defense mechanisms [22, 23]. The high immunoreactivity
of PBC patient sera against oral streptococci and the high
familial prevalenceofPBCsuggestnotonlyageneticetiology
but also a possible environmental transmission during
childhood via the mouth of a child’s parent. This theory
of transmission from parent to child, however, cannot fully
explain the dominant occurrence of PBC in women.
Considering the fact that the onset of PBC occurs during
t h eﬁ f t hd e c a d eo fl i f e[ 7] and that there is no apparent
antecedent infection related to PBC, as there is in GBS [3, 4],
the environmental etiopathology of bacteria in PBC may
possiblysuggestthechronicpersistenceoflow-immunogenic
or avirulent bacteria, commensally coexisting within the
host over the long term, rather than a severe yet transient
infection. In this sense, periodontitis isolates and other oral
colonizing bacteria satisfy these criteria. How do bacteria
in the oral cavity reach the liver? One possibility would be
a hematogenous transmission from the oral mucosal layer.
Since increased permeability of the stomach and the small
intestine is reported in PBC patients [24], transmission from
the intestinal tract via the portal vein to the liver should also
be an additional possibility.
3. Infection-Induced Mouse Model of PBC
Whereas strong evidence exists that bacterial infection may
trigger PBC, subsequent implications have been diﬃcult to
elucidate. Oral streptococcal isolates, namely, S. intermedius,
S. sanguinis,a n dStreptococcus mitis as well as Micrococ-
cus luteus and E. coli, were repeatedly used to inoculate
BALB/c mice, mimicking chronic bacterial exposure, and
pathological alterations in the liver and the production of
autoantibodies were investigated. The livers of mice at 8
weeks after inoculation with S. intermedius, S. sanguinis,
or S. mitis showed CNSDC-like inﬂammatory cellular inﬁl-
trates in the portal area [25]. When BALB/c mice were
left inoculation-free for an additional 20 months after the
completion of an initial 8 week-S. intermedius inoculation,
CNSDC-like portal inﬂammation was still observed [25].
LTA immunoreactivity was detectable in not all but some
of the cytoplasm of polymorphic inﬂammatory cells around
biliary epithelial cells and connective tissues around bile
ducts, and CD3-positive cells were predominantly observed
in the cellular inﬁltrates around the bile ducts. In the
portal area, LTA immunoreactivity was detectable in not all
but some of the cytoplasm of polymorphic inﬂammatory
cells around the biliary epithelial cells and connective
tissues around the bile ducts, and CD3-positive cells were
predominantly observed in the cellular inﬁltrates around
the bile ducts. Other tissue damages that are occasion-
ally associated with PBC were also detected. The salivary
glands of live S. intermedius-inoculated mice exhibited
Sj¨ ogren’s syndrome-like periductal lymphocytic inﬁltration
[25].
An investigation of PBC-like autoantibodies in our
model detected a high frequency of the production of anti-
gp210 antibodies, which are commonly detected in PBC
patients, especially those with a poor prognosis [26]. We
previously reported that IgM class antibody titers against
histone-like DNA-binding protein (HLP) of S. intermedius
were signiﬁcantly high in the sera of PBC patients and that
immunoreactivity to anti-S. intermedius-HLP was detected
in the cytoplasm of biliary epithelial cells and inﬂammatory
cells in the portal area of the livers of PBC patients
[20]. In S. intermedius-inoculated BALB/c mice, consistent
with observations in human patients, immunoreactivity
to S. intermedius-HLP was detected around the sites of
CNSDC in the portal area of the livers both soon after
and 8 weeks after S. intermedius inoculation. Furthermore,
the aﬃnity of anti-S. intermedius-HLP antibody to the c-
terminus synthetic peptide of gp210 was detected in a dose-
dependent and speciﬁc manner, suggesting cross-reactivity
between gp210 and S. intermedius-HLP [25]. These results
suggested that chronic exposure to S. intermedius couldISRN Gastroenterology 3
trigger PBC-like pathological alterations in BALB/c mice
resembling the pathology of PBC in humans.
4.AutoimmunePancreatitisand
IgG4-RelatedDiseases
Autoimmune pancreatitis (AIP) is another putative autoim-
mune disease of the hepatobiliary-pancreatic system and
is a chronically progressing inﬂammatory disease of the
pancreas [27, 28]. The morphological characteristics of AIP
include diﬀuse or localized enlargement of the pancreas
and irregular narrowing of the main pancreatic duct. His-
tologically, the disease is also associated with progressive
lymphoplasmacytic inﬁltration, predominantly localized to
the ductal structures, and varying degrees of parenchymal
and acinar destruction [29].
There are two types of AIP that diﬀer in their clinical
features, such as the gender ratio, mean age, and associated
immune-related diseases. Type 1 AIP is associated with
the histological ﬁnding of lymphoplasmacytic sclerosing
pancreatitis (LPSP). Its serological hallmark is an elevation
in the serum levels of the IgG4 subclass of IgG [27].
Type 1 AIP appears to be the pancreatic manifestation of
a systemic disease called IgG4-associated systemic disease
(ISD), aﬀecting not only the pancreas but also other organs
including the bile duct, retroperitoneum, kidney, lymph
nodes, and salivary glands [30]. Type 2 AIP is a form of
idiopathicchronic pancreatitis, histologically associated with
granulocyte-epithelial lesions [31]. The pathogenesis of AIP
remains unknown. Genetic associations between susceptibil-
ity to the disease and the human leukocyte antigen (HLA)
DRB1∗0405-DQB1∗0401 haplotype [32–34], Fc receptor-
likegene3(FCRL3)[35],andtheCTLA4gene[36]havebeen
suggested.
An outstanding ﬁnding in type 1 AIP is hypergam-
maglobulinemia and the existence of a high serum con-
centration for IgG4, which has been documented in 90%
of patients [37]. This occurs in parallel to an abundant
IgG4-positive plasma cell inﬁltration in the pancreatic
tissue [38]. The ﬁbroinﬂammatory process characterizing
AIP occurs at the pancreatic basement membranes where
IgG4/IgG/complement-immune complexes are deposited
[39]. AIP is occasionally associated with elevated circulating
immune complex levels, which are signiﬁcantly linked to
increased serum IgG1 and complement activation via the
classical pathway [33]. IgG4 is unable to activate the classical
pathway of complements but binds IgG1, 2, and 3 and forms
an Fc–Fc interaction immune complex in patients with AIP
[40]. Although the role of IgG4 in the immune response
and autoimmunity has not yet been fully elucidated, it
may be hypothesized that IgG4 blocks the Fc-mediated
eﬀector functions of IgG1 and dampens the inﬂammatory
response to an as-yet-unidentiﬁed primary trigger of the
inﬂammatory process in AIP [40, 41].
5.AutoantibodiesinAIP
To which antigens the immunoglobulins in the deposits
along the basal membranes of the pancreatic ducts and
acini react remains unclear. Circulating antibodies in AIP
include autoantibodies against carbonic anhydrase- (CA-) II
[62], CA-IV [63], lactoferrin (LF) [62], pancreatic secretary
trypsin inhibitor (PSTI) [64], and heat shock protein-
(HSP-) 10 [65]. Thymectomized mice immunized with
CA-II or LF develop a pathology that closely resembles AIP
under a regulatory T cell- (Treg-) depleted background [54].
However, T cells speciﬁc for CA-II and LF were unable to
induce pancreatitis in the adoptive transfer of an amylase-
speciﬁc rat model [52], implying that autoantibodies against
these enzymes in AIP represent a late consequence of tissue
destruction and perhaps not a fundamental pathogenic
mechanism. Additionally, these potential antigens reside in
the cytoplasm of pancreatic cells and are not associated
with the basement membranes targeted for the ﬁbroin-
ﬂammatory process in AIP [39]. Moreover, the major
subclasses of these autoantibodies in the sera of patients
with AIP are classiﬁed as the IgG1 subtype, and not IgG4
[33, 40, 64]. This implies that these antigens may be
secondarily involved in the AIP immune process, as it is
directed toward still-unknown antigens in pancreatic basal
membranes.
6.Innate Immunity Sensitized by Infectious
AgentsintheEtiologyof AIP
Although the initial events triggering AIP are not known,
thepancreaticcellsmaybecometargetsofimmune-mediated
processes through viral or other infectious agents. Guarneri
et al. showed a signiﬁcant homology between human CA-II
and α-CA of H. pylori. Moreover, the homologous segments
contained the binding motif of DRB1∗0405 [66]. Notably,
the possession of the HLA DRB1∗0405-DQB1∗0401 geno-
type confers a risk for AIP development [32]. Frulloni
et al. reported that 94% of AIP patients, but only 5%
of pancreatic cancer patients, exhibit IgG antibodies to a
plasminogen-binding protein (PBP) that is homologous to
thehumanproteinubiquitin-proteinligaseE3componentn-
recognin 2 (UBR2), which is expressed in pancreatic acinar
cells and is also homologous to the PBP of H. pylori [67].
These data suggest that H. pylori infection may trigger AIP
in genetically predisposed subjects through autoimmune
responses triggered by molecular mimicry.
Several experimental models of AIP have been described
(Table 1). Virus-induced AIP models, such as C57BL/6
mice infected with the murine leukemia retrovirus LP-BM5,
developed histological ﬁndings similar to human AIP [59,
60]. The spontaneous development of pancreatitis via an
autoimmune mechanism in MRL/Mp mice is accelerated by
the administration of polyinosinic:polycytidylic acid (poly
I:C),a synthetic double-strandedRNAandTLR3ligand [55–
58]. Sensitization occurs with not only viral components,
such as double-stranded RNA poly I:C, but also bacterial
LPS-induced pancreatitis in interleukin- (IL-) 10-deﬁcient
mice[55].TLRsplayimportant rolesininnateimmunityand
initiate intracellular signaling to macrophages and dendritic
cells after stimulation with various antigens. The majority of
known TLRs mediate the development of Th1 cell-inducing
dendritic cells [68]. Hence, pattern-recognition receptors4 ISRN Gastroenterology
Table 1: Experimental animalmodels of autoimmune pancreatitis.
Animal Organs with lesions Induction Target antigen Eﬀector cells References
MRL/lpr mice Pancreas Spontaneous ? T cells
[42]
Pancreas, salivary gland [43]
aly/aly mice
Pancreas, salivary gland,
lung Spontaneous ? CD4+ T cells [44]
Pancreas [45, 46]
WBN/Kob rats, male Pancreas, salivary gland,
bile duct Spontaneous ? CD8+ T cells [47]
MHC-II−/− mice Pancreas Spontaneous ? CD8+ T cells [48]
T-cell+ HLADR∗0405Ab0
NOD mice Pancreas, lung Spontaneous ? T cells [49]
Tgfbr2(fsp KO ) mice Pancreas, salivary gland Spontaneous ? T cells [50]
NOD.CD28KO mice Pancreas Spontaneous Amylase CD4+ T cells [51]
DA(RP) rats
Lewis rats
?
Pancreas
Amylase-
speciﬁc
Tc e l l
? CD4+ and CD8+
T cells [52]
PL/J mice (H-2s,H - 2 u) Pancreas, salivary gland,
kidney CA-II CA-II ? [53]
nTx-BALBc mice Pancreas, salivary gland,
bile duct, kidney CA-II CA-II CD4+ Th1 cells [54]
nTx-BALBc mice Pancreas, salivary gland,
bile duct, kidney LF LF CD4+ Th1 cells [54]
MRL/Mp, MRL/lpr mice Pancreas, salivary gland,
bile duct, kidney ?C D 4 + T cells [57]
MRL/Mp mice Pancreas, salivary gland,
liver Poly I:C PSTI ? [58]
Pancreas ? ? [55]
IL-10KO mice Pancreas Poly I:C, LPS ? ? [55]
C57BL/6 mice Pancreas, salivary gland,
liver, kidney, lung LP-BM5 ? CD4+ T cells [59, 60]
C57BL/6 mice Pancreas, salivary gland E. coli ? T cells [61]
CA-II:carbonicanhydraseII;LF:lactoferrin;PSTI:pancreaticsecretarytrypsininhibitor;polyI:C:polyinosinicpolycytidylicacid;nTx:neonatalthymectomy.
Modiﬁed from [28, 29].
(PRRs) that bind pathogen-associated molecular patterns
(PAMPs) may trigger an autoimmune response.
7. Infection-Induced Mouse Model of AIP
We previously reported that when C57BL/6 mice were
inoculated intraperitoneally (i.p.) with heat-killed E. coli
weekly for 8 weeks, marked cellular inﬁltration with ﬁbrosis
was observed in the exocrine pancreas accompanied by a
high serum gamma-globulin level and the production of
autoantibodies against CA-II and LF. Bacterial infection
apparently triggered autoimmune pancreatitis-like patho-
logical alterations in mice that strikingly resembled AIP in
humans [61].
C57BL/6 mice inoculated weekly with E. coli for 8 weeks
were utilized as donors, and the spleens were intravenously
transferred to RAG2−/− mice. The pancreas in the recipient
RAG2−/− mice showed cellular inﬁltration in the exocrine
pancreas, especially around the pancreatic ducts, indicating
that the E. coli-inoculated mouse spleen cells possess the
ability to reproduce pathological alterations in the pancreas
of na¨ ıve mice. Similarly, when the spleen cells of donor
S. intermedius-inoculated mice were transferred to RAG2−/−
mice, CNSDC-like cholangitis in the liver was induced,
similar to that seen in the donor [61].
T h eA I P - l i k ei n ﬂ a m m a t o r yr e g i o ni nt h ep a n c r e a s e so f
recipient mice with spleen cells transferred from E. coli-
inoculated mice [61], as well as the CNSDC-like inﬂam-
matory region in the livers of recipient mice with spleen
cells transferred from S. intermedius-inoculated mice [25],
both showed that most of the cellular inﬁltrates in the target
organs were CD3 positive, indicating that these cells in
both models originated from the donor mice. The ﬁndings
observed indicated that our animal models of PBC and AIP
are of autoimmune etiology.
The criteria for determining whether a condition may
be considered to be autoimmune, according to Witebsky’s
postulates with modern revision by Rose and Bona [69],
include (i) indirect evidence based on the reproduction of
the autoimmune disease in experimental animals, (ii) direct
evidence of the transfer of pathogenic antibodies, or
(iii) pathogenic T cells and indirect evidence of the isolationISRN Gastroenterology 5
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Figure 1: Hypothetical pathogenesis of PBC and AIP. During the initiation phase, weak but silently inﬁltrating PAMPs and/or antigen(s),
such as avirulent bacteria, trigger and upregulate the innate immune system. Second, the progressive phase features the persistence of this
PAMP attack or stimulation by molecular mimicry and/or exposure or stimulation from commensal ﬂora possessing the same antigenic
epitope thatthe initialpathogenand/orPAMP possessed,thereby upregulating thehostimmuneresponse to thetarget antigen.These slowly
progressive steps eventually lead to the development of autoimmunediseases. Modiﬁed from previous papers [25, 61].
of autoantibodies or autoreactive T cells. Several lines of
evidence have established our animal models to be of
autoimmune origin. The current approach in our research
is to search for a possible supply of antigenic stimulant that
is similar to or that will cross-react with autoantigens in vivo;
so far we have narrowed our search down to bacterial species
possessing a candidate epitope.
8.Conclusions
We propose a hypothetical pathogenetic mechanism for
bacteria-induced PBC and AIP. During the initiation phase,
weak but silently inﬁltrating PAMPs and/or antigen(s), such
as avirulent bacteria, trigger and upregulate the innate
immune system. Second, the progressive phase features the
persistence of this PAMP attack or stimulation by molecular
mimicry and/or exposure or stimulation from commensal
ﬂora possessing the same antigenic epitope that the initial
pathogen and/or PAMP possessed, thereby upregulating the
host immune response to the target antigen. These slowly
progressive steps eventually lead to the development of
autoimmune diseases (Figure 1).
Recently, NOD.c3c4 [70], TGFb receptor II dominant-
negative [71], IL-2 receptor α knockout [72], and Ae2a,b-
deﬁcient mice [73] have been reported as spontaneous
PBC animal models. The spontaneous development of AIP
in T-cell-competent HLA-DR∗0405 transgenic Ab0 NOD
mice [49], Treg-deﬁcient backgroundsin neonatally thymec-
tomized mice [54], NOD.CD28 knockout mice [51], and
Tgfbr2fsp knockout mice [50] have demonstrated genetic
polymorphisms of the eﬀector cells in the etiologies of AIP.
However, as these mice are genetically engineered, they may
not completely reﬂect the onset of human diseases. Our
models of PBC and AIP developed in genetically normal
BALB/c and C57BL/6 mice, respectively, by the inoculation
ofhuman commensal bacteriaare more clinicallyrelevant,as
they reﬂect the conditions of human patients, and should be
useful for advancing our understanding of the pathological
mechanism(s) underlying PBC and AIP.
Under normal conditions, commensal bacteria are not
pathogenic and in fact may inhabit the host from early
life. Commensal bacteria in the gastrointestinal tract have
been recognized to interact with the innate immune system
and to drive regulatory T-cell diﬀerentiation [74, 75].
The fact that commensal bacteria can induce autoimmune
diseases associated with genetic polymorphisms, immune
susceptibility, and other environmental factors may expand
our concept of the pathoetiology of autoimmune diseases.
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